Clinical effect of Nimodipine combined with rosuvastatin calcium in the treatment of hypertensive cerebral hemorrhage
尼莫地平联合瑞舒伐他汀钙治疗高血压性脑出血的临床效果

摘要

目的 本研究旨在评估尼莫地平与瑞舒伐他汀钙联合治疗高血压性脑出血（HICH）的疗效。方法 于2023年12月，选取我院神经外科100例HICH患者，依据随机数字表，均分为两组：对照组、观察组，各含50例。对照组采用常规治疗联合尼莫地平治疗，观察组在对照组基础上加用瑞舒伐他汀钙。治疗周期为14天。通过比较两组治疗前后的血肿量、水肿体积、NIHSS和ADL评分、超氧化物歧化酶和丙二醛水平，以及不良反应和预后结局，评估两种治疗方案的疗效。结果 观察组治疗总有效率高于对照组（P＜0.05）。治疗14天后，观察组的血肿量、水肿体积较对照组明显降低，NIHSS评分明显降低，ADL评分明显升高，SOD水平升高，MDA水平降低（P＜0.05）。此外，观察组的轻度残疾率高于对照组，重度残疾率低于对照组（P＜0.05）。结论 尼莫地平与瑞舒伐他汀钙联用，对HICH疗效卓著，可加速血肿及水肿消弭，优化神经功能状态，降低氧化应激水平，且安全性较高，值得推广使用。

Abstract

Objective This study was to evaluate the efficacy of nimodipine combined with rosuvastatin calcium in the treatment of hypertensive intracerebral hemorrhage (HICH).
Methods In December 2023, 100 patients with HICH in neurosurgery department of our hospital were selected and divided into two groups according to random number table: control group and observation group, each containing 50 cases. The control group was treated with conventional treatment combined with nimodipine, and the observation group was treated with rosuvastatin calcium on the basis of control group. The treatment period was 14 days. By comparing the hematoma volume, edema volume, NIHSS and ADL scores, superoxide dismutase and malondialdehyde levels before and after treatment, as well as adverse reactions and prognostic outcomes, the efficacy of the two treatment regimens was evaluated.
Results The total effective rate of observation group was higher than that of control group (P < 0.05). After 14 days of treatment, the hematoma volume and edema volume in the observation group were significantly lower than those in the control group, the NIHSS score was significantly lower, the ADL score was significantly higher, the SOD level was increased, and the MDA level was decreased (P < 0.05). In addition, the mild disability rate in the observation group was higher than that in the control group, and the severe disability rate was lower than that in the control group (P < 0.05).
Conclusion   Nimodipine combined with rosuvastatin calcium has excellent efficacy in the treatment of HICH, can accelerate the reduction of hematoma and edema, optimize neurological function, reduce oxidative stress level, and is safe, worthy of promotion.